[go: up one dir, main page]

ES2538817T3 - Método para la inducción simultánea de CTL y células gamma delta T - Google Patents

Método para la inducción simultánea de CTL y células gamma delta T Download PDF

Info

Publication number
ES2538817T3
ES2538817T3 ES09773177.2T ES09773177T ES2538817T3 ES 2538817 T3 ES2538817 T3 ES 2538817T3 ES 09773177 T ES09773177 T ES 09773177T ES 2538817 T3 ES2538817 T3 ES 2538817T3
Authority
ES
Spain
Prior art keywords
cells
ctl
gamma delta
simultaneous induction
peripheral blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09773177.2T
Other languages
English (en)
Inventor
Mie Nieda
Mai Tomiyama
Masato Muto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinet Co Ltd
Original Assignee
Medinet Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co Ltd filed Critical Medinet Co Ltd
Application granted granted Critical
Publication of ES2538817T3 publication Critical patent/ES2538817T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Mycology (AREA)

Abstract

Un método in vitro para producir una población celular mixta de CTL específicos de antígeno de enfermedad y células γ δT, en que el método comprende las etapas de: añadir un antígeno de enfermedad y un aminobifosfonato a una población de células mononucleares de sangre periférica y cultivar las células mononucleares de sangre periférica resultantes que comprenden dichos CTL específicos de antígeno de enfermedad y células γ δT.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES09773177.2T 2008-07-01 2009-06-30 Método para la inducción simultánea de CTL y células gamma delta T Active ES2538817T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008172797 2008-07-01
JP2008172797 2008-07-01
PCT/JP2009/003039 WO2010001599A1 (ja) 2008-07-01 2009-06-30 ＣＴＬとγδＴ細胞の同時誘導方法

Publications (1)

Publication Number Publication Date
ES2538817T3 true ES2538817T3 (es) 2015-06-24

Family

ID=41465706

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09773177.2T Active ES2538817T3 (es) 2008-07-01 2009-06-30 Método para la inducción simultánea de CTL y células gamma delta T

Country Status (9)

Country Link
US (1) US8962313B2 (es)
EP (1) EP2311470B1 (es)
JP (1) JP5524056B2 (es)
CN (1) CN102137925B (es)
DK (1) DK2311470T3 (es)
ES (1) ES2538817T3 (es)
HU (1) HUE027084T2 (es)
PT (1) PT2311470E (es)
WO (1) WO2010001599A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101217706B1 (ko) * 2004-07-08 2013-01-02 가부시키가이샤 메디넷 수상세포, 상기 수상세포를 포함하는 의약, 상기수상세포를 사용한 치료방법 및 γδＴ세포의 배양방법
ES2460627T3 (es) 2010-06-04 2014-05-14 Opulent Electronics International Pte Ltd. Dispositivo y procedimiento de activación de LED
WO2012099093A1 (ja) * 2011-01-21 2012-07-26 株式会社日本バイオセラピー研究所 Nk細胞強化型血液製剤の製造方法
JP5825966B2 (ja) * 2011-10-11 2015-12-02 株式会社日本バイオセラピー研究所 Ｃｄ５６陽性ｔ細胞増強方法
CA2926859A1 (en) 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
CN103768595B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
CN107106578B (zh) * 2014-08-12 2020-12-25 香港大学 治疗厄泼斯坦-巴尔病毒相关疾病的双膦酸盐化合物和γδT细胞-介导的疗法
CN106795493A (zh) * 2014-10-06 2017-05-31 堤乐哈修门医学研究基础建设及服务有限公司 使用双膦酸盐、抗cd3抗体和il‑2扩增t细胞群体
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108949685B (zh) * 2018-08-02 2022-03-29 吉林大学第一医院 一种体外诱导扩增高杀伤活性γδT细胞的方法
EP3856206A1 (en) 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469274A1 (en) 2001-12-10 2003-06-19 Kyogo Itoh Tumor antigens
US20050048646A1 (en) 2003-08-25 2005-03-03 Medinet Co., Ltd. Method for inducing cytotoxic T lymphocyte
KR101217706B1 (ko) 2004-07-08 2013-01-02 가부시키가이샤 메디넷 수상세포, 상기 수상세포를 포함하는 의약, 상기수상세포를 사용한 치료방법 및 γδＴ세포의 배양방법
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
KR101419711B1 (ko) * 2005-09-08 2014-07-17 가부시키가이샤 메디넷 항원제시세포의 활성화 처리방법

Also Published As

Publication number Publication date
EP2311470B1 (en) 2015-05-27
JPWO2010001599A1 (ja) 2011-12-15
JP5524056B2 (ja) 2014-06-18
PT2311470E (pt) 2015-07-09
CN102137925B (zh) 2014-12-10
DK2311470T3 (en) 2015-08-17
EP2311470A1 (en) 2011-04-20
US20120107292A1 (en) 2012-05-03
WO2010001599A1 (ja) 2010-01-07
EP2311470A4 (en) 2013-05-08
CN102137925A (zh) 2011-07-27
US8962313B2 (en) 2015-02-24
HUE027084T2 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
ES2538817T3 (es) Método para la inducción simultánea de CTL y células gamma delta T
Sadik et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression
ES2505119T3 (es) Lámina posterior de soporte para módulos fotovoltaicos
Ando et al. Evaluating CAR‐T cell therapy in a hypoxic 3D tumor model
Sanos et al. RORγt and commensal microflora are required for the differentiation of mucosal interleukin 22–producing NKp46+ cells
ES2633246T3 (es) Composición para el tratamiento del cáncer de próstata (PCa)
ES2491891T3 (es) Marcaje celular para técnicas de resonancia magnética nuclear
Maiuri et al. The first world cell race
ES2507520T3 (es) Aislamiento y/o identificación de células madre con potencial de diferenciación adipocitario, condrocitario y pancreático
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2560470T3 (es) Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
ES2579954T3 (es) Ensayo para el descubrimiento de fármacos basado en células diferenciadas in vitro
Gohda et al. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer’s patches for intestinal IgA responses
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
Zangle et al. Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity
CO6640286A2 (es) Proceso in vitro para la determinacion rapida en un paciente del estado de infeccion con mycrobacterium tuberculosis
EP2595967A4 (en) TETRAZIN TRANS CYCLOOCTS LIGATION FOR FAST CONSTRUCTION OF RADIONUCLIDED TAGS
JP2014507664A5 (es)
Rajaei et al. Effect of 1, 25 (OH) 2 vitamin D3 on cytokine production by endometrial cells of women with repeated implantation failure
Singh et al. Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer
ES2660763T3 (es) Sonda codificada genéticamente para la cuantificación de la concentración de piruvato y métodos de utilización del mismo
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
Parney et al. Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
Poh et al. Rapid generation of functional nanovesicles from human trophectodermal cells for embryo attachment and outgrowth
WO2007146811A3 (en) Assessment of cellular composition and fractional viability and uses thereof